Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 3/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.33 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.31 |
| ▸ | CCR1 | P32246 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18611221 | 0.82 | METTL3 (0.30) | METTL3 | |
| SCHEMBL7996504 | 0.82 | HDAC1 (0.32) | HDAC1HDAC7METTL3 | |
| SCHEMBL17911156 | 0.82 | METTL3 (0.30) | METTL3 | |
| SCHEMBL18169175 | 0.80 | HDAC1 (0.34) | HDAC1HDAC7METTL3 | |
| SCHEMBL23642505 | 0.78 | FFAR1 (0.34) | HDAC1P2RX7 | |
| SCHEMBL24777116 | 0.78 | METTL3 (0.34) | HDAC1HDAC7METTL3 | |
| SCHEMBL28281002 | 0.78 | METTL3 (0.32) | HDAC1HDAC7METTL3 | |
| SCHEMBL24335765 | 0.75 | FYN (0.35) | HDAC1HDAC7 | |
| SCHEMBL24914936 | 0.74 | KDM4E (0.35) | — | |
| SCHEMBL23793192 | 0.74 | HDAC1 (0.30) | HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025043225-A2 | DEGRADERS OF CYCLIN-DEPENDENT KINASE 2 | GENENTECH, INC. (US) | 2025-02-27 | — | — | WO | disclosed |
| US-20240287070-A1 | FUSED HETEROCYCLIC DERIVATIVES | JOHNSON & JOHNSON (CHINA) INVESTMENT LTD. (CN) | 2024-08-29 | — | — | US | disclosed |
| US-20240279227-A1 | FUSED HETEROCYCLIC DERIVATIVES | JANSSEN BIOTECH, INC. | 2024-08-22 | — | — | US | disclosed |
| EP-4347590-A1 | FUSED HETEROCYCLIC DERIVATIVES | Janssen Sciences Ireland Unlimited Company (IE) | 2024-04-10 | — | — | EP | disclosed |
| EP-4347036-A1 | FUSED HETEROCYCLIC DERIVATIVES | Janssen Sciences Ireland Unlimited Company (IE) | 2024-04-10 | — | — | EP | disclosed |
| US-20230355626-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2023-11-09 | — | — | US | disclosed |
| US-20230145793-A1 | SUBSTITUTED PYRIMIDINE OR PYRIDINE AMINE DERIVATIVE, COMPOSITION THEREOF, AND MEDICAL USE THEREOF | SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2023-05-11 | — | — | US | disclosed |
| US-20230145793-A1 | SUBSTITUTED PYRIMIDINE OR PYRIDINE AMINE DERIVATIVE, COMPOSITION THEREOF, AND MEDICAL USE THEREOF | SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2023-05-11 | — | — | US | disclosed |
| EP-4122927-A1 | SUBSTITUTED PYRIMIDINE OR PYRIDINE AMINE DERIVATIVE, COMPOSITION THEREOF, AND MEDICAL USE THEREOF | Shanghai Haiyan Pharmaceutical Technology Co., Ltd. (CN) | 2023-01-25 | — | — | EP | disclosed |
| EP-4114834-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2023-01-11 | — | — | EP | disclosed |
| CN-115551858-A | Inhibitors of human immunodeficiency virus replication | VIIV保健英国第五有限公司 | 2022-12-30 | — | — | CN | disclosed |
| WO-2022253255-A1 | FUSED HETEROCYCLIC DERIVATIVES | Janssen Sciences Ireland Unlimited Company (IE) | 2022-12-08 | — | — | WO | disclosed |
| WO-2022253255-A1 | FUSED HETEROCYCLIC DERIVATIVES | Janssen Sciences Ireland Unlimited Company (IE) | 2022-12-08 | — | — | WO | disclosed |
| WO-2022253259-A1 | FUSED HETEROCYCLIC DERIVATIVES | Janssen Sciences Ireland Unlimited Company (IE) | 2022-12-08 | — | — | WO | disclosed |
| WO-2022253259-A1 | FUSED HETEROCYCLIC DERIVATIVES | Janssen Sciences Ireland Unlimited Company (IE) | 2022-12-08 | — | — | WO | disclosed |
| WO-2021176366-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2021-09-10 | — | — | WO | disclosed |
| CN-111372936-A | Mcl-1 selective inhibitors, their preparation and use | 北京赛林泰医药技术有限公司 | 2020-07-03 | — | — | CN | disclosed |
| CN-110452253-A | Mcl-1 selective depressant and its preparation and use | CENTAURUS BIOPHARMA CO LTD | 2019-11-15 | — | — | CN | disclosed |
| WO-2019101144-A1 | SELECTIVE MCL-1 INHIBITOR AND PREPARATION AND USE THEREOF | 北京赛林泰医药技术有限公司 | 2019-05-31 | — | — | WO | disclosed |
| CN-109824690-A | Mcl-1 selective depressant and its preparation and use | 北京赛林泰医药技术有限公司 | 2019-05-31 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240287070-A1 | FUSED HETEROCYCLIC DERIVATIVES | HAVCR2, HCCS, GOT2 | NOTUM 3827/4885HDAC1 1277/4885HDAC7 1626/4885 |
| US-20240279227-A1 | FUSED HETEROCYCLIC DERIVATIVES | HAVCR2, HCCS, GOT2 | NOTUM 3827/4885HDAC1 1277/4885HDAC7 1626/4885 |
| US-20230145793-A1 | SUBSTITUTED PYRIMIDINE OR PYRIDINE AMINE DERIVATIVE, COMPOSITION THEREOF, AND MEDICAL USE THEREOF | ADORA2A, ADORA2B, ADORA3 | NOTUM 3954/4885HDAC1 4113/4885HDAC7 3277/4885 |
| US-20230355626-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | EIF2AK2, POLR2E, POLR2H | NOTUM 2229/4885HDAC1 488/4885HDAC7 1242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.